Microsure, innovation leader in robot-assisted microsurgery, announced today the successful closing of its Series B2 investment round securing €38 million in development capital. With this funding, Microsure will finalize the development of its newest microsurgical robot MUSA-3 for clinical studies, followed by FDA clearance in the USA and CE-mark in Europe. As part of this financing round, Kreske Nickelsen from new investor kineo will join the supervisory board, further strengthening Microsure’s governance.
Microsure’s groundbreaking microsurgical robot MUSA-3 is designed to revolutionize the field of open microsurgery, helping microsurgeons excel and leave no patient untreated. It represents a monumental leap in microsurgical technology, poised to empower surgeons with unprecedented precision, stability and control beyond human capabilities, elevating patient care to new heights in the future of microsurgery. Building on the success of MUSA-2, MUSA-3 offers enhanced dexterity and a wide workspace, tremor reduction for enhanced precision and seamless integration with surgeons’ existing preferred micro-instruments of different well-known top brands. Its adaptability allows it to be used in a wide range of surgical procedures. MUSA-3 combines surgeon comfort with improved ergonomics, enabling surgeons to work from a surgeon console with digital exoscopes or hybrid surgical microscopes.
The financing round welcomes a host of new investors, including the European Innovation Council Fund (EICF), kineo, Invest-NL, and several prominent private investor groups. Microsure also acknowledges the unwavering support of key existing shareholders including deep-tech venture capital firm Innovation Industries, BOM Ventures, private investors Ten Cate Investerings Maatschappij (TCIM), Venturing Tech, Eindhoven University of Technology (TU/e), and Microsure Founders. This fundraising not only solidifies Microsure’s financial foundation but also reflects the confidence of all investors in the company’s groundbreaking technology.
Microsure’s commitment to innovation has also been recognized with an EIC Accelerator grant, and an Innovation Loan from RvO, a division of the Dutch Ministry of Economic Affairs, further affirming its pioneering role in the medical technology sector. Additionally, the company has entered into an asset financing agreement with kineo, enabling Microsure to offer appealing leasing options to hospitals adopting MUSA-3, Microsure’s first commercial product.
Building upon a legacy of excellence, Microsure is proud to highlight several clinical studies with the clinical prototype, MUSA-2. These studies, performed at Maastricht University Medical Center in the Netherlands and Uppsala Academic Hospital in Sweden include about 50 patients to date and encompass a wide spectrum of surgical indications, yielding promising results and invaluable insights for the development of MUSA-3. In addition, an in-vitro study in Uppsala featuring 20 microsurgeons performing over 200 anastomoses reveals a remarkably swift learning curve using MUSA. Other in-vitro studies underscore the ergonomic benefits for surgeons and also the benefits of the technology for neurosurgical applications.
Svetoslava Georgieva, Chair of the EIC Fund Board, comments:
“We are glad to support Microsure through this investment round. We believe they can make a significant difference in the lives of patients in need of microsurgery. With the current funding round, we are confident that Microsure’s team will be able to successfully introduce MUSA-3 to the EU markets.”
Sjaak Deckers, CEO of Microsure, emphatically states:
“We extend our deep gratitude to both our new and steadfast existing investors for their unwavering support, which has propelled Microsure to new heights. The financing will enable us to advance our groundbreaking technology and bring innovative solutions to patients worldwide through our MUSA-3 robotic system.”
“The tireless efforts of the Microsure team over the past years have culminated in the development of a truly unique robot celebrated for its precision, ergonomic design, and adaptability for a wide spectrum of intricate procedures.”
“Our progress is a testament to the exceptional talent within our growing team of dedicated individuals and the seamless collaboration with our key development and manufacturing partners. The continued expansion of Microsure’s clinical network strategically positions the company for upcoming clinical studies, an integral part of our journey towards securing FDA clearance and CE-mark certification.”
